Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Liabilities

Other segment segments

Holding Company
$4.87B-4.1%
Energy
$3.16B-10.5%
Investment
$1.42B-24.3%
Automotive
$747M-7.9%
Food Packaging
$238M-7.0%
Home Fashion
$64M+18.5%

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Icahn Enterprises's pharma — liabilities.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Icahn Enterprises's pharma — liabilities?
Icahn Enterprises (IEP) reported pharma — liabilities of $61M in Q1 2026.
How has Icahn Enterprises's pharma — liabilities changed year-over-year?
Icahn Enterprises's pharma — liabilities increased by 3.4% year-over-year, from $59M to $61M.
What is the long-term trend for Icahn Enterprises's pharma — liabilities?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — liabilities has grown at a 5.2% compound annual growth rate (CAGR), from $202M to $247M.
What does pharma — liabilities mean?
The total financial obligations and debts owed by the pharmaceutical segment to external parties. This figure encompasses both current operational payables and long-term debt or other financial commitments. It is a key measure of the segment's financial leverage and risk profile.